Drugs / LCPUFA Oil Supplement
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04312932 | Dec 2021 → Nov 2023 | autism spectrum disorder | Sarah Keim | Completed | No outcome recorded |
| Phase 2 | NCT03550209 | Jun 2018 → Jan 2020 | autism spectrum disorder | Sarah Keim | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LCPUFA Oil Supplement | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03550209 ↗ |
| Known as | Omega 3-6 oil | “25 mg/kg, 50 mg/kg, or 75 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days” NCT04312932 ↗ |
| Modality | Other / unclassified | “Fatty acid supplements are natural products” NCT04312932 ↗ |
| Route | Oral | “to be administered twice per day by mouth for 90 days” NCT03550209 ↗ |